Open access
Jul 2026
In silico pipeline for GSK 3β inhibitor discovery in Alzheimer’s disease using pharmacophore screening, docking, ADME filtering, and MD validation
These findings identify SB1 and LB1 as promising, safe, and brain-penetrant GSK-3β lead compounds for experimental validation in Alzheimer’s disease.
Mahmoud S. Elkotamy, Mohamed K. Elgohary, Ahmed S. Alkotami et al.
· Scientific Reports · 0 citations